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Summary.-The hypoxic cell radiosensitizer, Ro 07-0582, has now been given in
multiple doses to 16 patients. They have received a total of 15-51 g in 3-20 doses.
Immediate tolerance was good, and satisfactory plasma levels of the drug were
consistently obtained. Neurotoxicity was, however, troublesome: convulsions
occurred in the patient given the highest dose, and there was peripheral neuropathy
in 11 cases. Tumour concentrations similar to those in plasma were obtained in
human tumours, in contrast to the findings in mouse tumours where concentrations
are usually below 40% of plasma levels. In the treatment of human tumours, a
lower dose of Ro 07-0582 should give useful hypoxic cell sensitization. Although the
total dose of Ro 07-0582 must be limited, there is a real prospect that it will give
benefit in clinical radiotherapy.
THE 2-nitroimidazole, Ro 07-0582, is
an effective radiosensitizer of hypoxic
cells and, in 16 different animal tumour
systems, a highly significant improvement
in tumour control has been achieved
(Adams and Fowler, 1976).
These promising results led to the
administration of the drug in single
doses to man. A successful trial in
normal volunteers was followed by its
administration to 10 patients (Foster et
al., 1975). Serum levels of an order
which, in animals, had given radio-
sensitization were achieved in all 8 cases
given doses between 4 and 10g (80-165
mg/kg body wt.) (Gray et al., 1976).
Although the highest doses gave rise to
some nausea and vomiting, the drug was
otherwise well tolerated. The radiation
response in skin made temporarily hypoxic
showed that, in man, Ro 07-0582 was
an effective radiosensitizer of hypoxic
cells (Dische, Gray and Zanelli, 1976).
Observations of tumour response in
3/7 patients with multiple deposits of
tumour gave evidence of enhancement
of effect by Ro 07-0582.
It was concluded from these studies
that the drug showed good promise as a
radiosensitizer in clinical radiotherapy
(Thomlinson et al., 1976).
This paper records the findings of
the next stage in the testing of Ro
07-0582: its administration in multiple
doses. When planning the work, we
anticipated that three major problems
might be encountered. Firstly, nausea
and vomiting was troublesome in the
single-dose study, particularly when the
drug was administered in amounts ex-
ceeding 140 mg/kg body wt. A reduction
in dose, to a maximum of 120 mg/kg,
was one conclusion from that study. It
was not known whether these gastro-
intestinal symptoms would lessen or
become more severe with repeated dosage.
Secondly, there was a suggestion that,
in primates, repeated administration led
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to a reduction in peak serum values,
possibly through enzyme inductionleading
to a more efficient destruction of the
drug (Johnson et al., 1976). However,
other work in primates indicated that,
with the dose and frequency ofadministra-
tion likely to be used in man, this would
not occur (Parkes, personal communica-
tion). Finally, there was evidence in
toxicological work in dogs (Scharer, 1972)
and primates (Parkes, personal communi-
cation) that Ro 07-0582 was neurotoxic,
in common with some other nitroimid-
azoles. Convulsions occurred with re-
peated high dosage. The dosage and
frequency of administration planned for
patients would need to be well below
that giving toxic effects in the primates,
so that, if tolerance were similar, a good
margin of safety would be allowed.
The two commonly used regimes for
clinical radiotherapy in our unit are 20
to 30 fractions, treating daily from
Monday to Friday over 4 to 6 weeks,
or 6 fractions treating twice weekly over
17 to 18 days. It seemed desirable that
the administration of Ro 07-0582 should
conform to these patterns, so that it
would prove practicable to employ it in
clinical work.
Between 14 October 1975 and 15 July
1976, a total of 21 patients was given
Ro 07-0582. Five were, however, given
no more than two doses. One of them
was given a single dose in a study of the
response of multiple skin nodules, and
another a single dose combined with
radiotherapy for a recurrent tumour of
the bladder. One further patient was
given two doses in an exploration of the
use of local hyperthermia, Ro 07-0582
and radiotherapy. Two final patients
showed general deterioration, due to co-
existing disease in one and multiple
metastases in the other, and further
Ro 07-0582 was not given. None of the
5 showed any symptom or sign which
could be related to toxicity of Ro 07-0582.
This report is concerned with the remain-
ing 16 patients who were given from 15
to 51 g of Ro 07-0582 in 3-20 doses.
METHOD
The patients selected presented advanced
malignant disease where long-term survival
was not expected. In most cases the
patients were generally well, with only
localized disease, in contrast to the patients
with widespread metastases included in the
single-dose study. The purpose of the work
was explained to the patients, who gave their
full consent.
All patients were carefully examined,
with special emphasis upon the central
nervous system. Observations were made
before treatment, during its course and in
follow-up. An isotope brain scan was rou-
tinely included as part of the pre-treatment
investigation.
As a rule, patients were given a light
breakfast and no restriction made upon
fluid intake. The Ro 07-0582 was given
between 10 and 10.30 a.m., preceded by a
10-mg oral dose of metoclopramide as an
antinauseant and to help gastric emptying,
as in the single-dose study.
The Ro 07-0582 was supplied by Roche
Products Ltd. in 500-mg tablets. It was
found in this series that most patients pre-
ferred to swallow the tablets, although in
two cases they were crushed and given as a
suspension.
After the initial dose, heparinized blood
samples were taken half-hourly, or at least
hourly, for 4 h and then at 6, 8 and 24 h,
for the determination of Ro 07-0582. Urine
was collected for 48 h, and the excretion
of the drug determined. In patients given
up to 6 doses, the same observations were
made after each administration. In patients
given daily doses, a more limited monitoring
was followed, but this included a complete
study after the first dose of each week.
The techniques for the determination of
Ro 07-0582 concentration have been de-
scribed (Foster et at., 1975 and Flockhart,
Large and Troup, in preparation).
Radiotherapy was given 31 to 4 h after
administration of Ro 07-0582, as in the
previous work. Study was made of skin
reaction, using a radio-strontium plaque,with
the skin either fully oxygenated or made
hypoxic. Thisworkwill bereportedseperately.
In 3 patients, serial samples of tumour
were assayed for concentration of Ro 07-
0582. The Morrison-Deeley high speed air
drill was used in two cases and scalpel
biopsy in the third.
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RESULTS
The total amount of Ro 07-0582,
the frequency and the timing of the
doses was modified as the work pro-
ceeded. The first regime employed was
based upon the single-dose study, to
give the size of the individual dose, and
upon the toxicological study in primates,
to determine the safe total in repeated
dosage.
A patient with a far-advanced rectal
carcinoma, considered to have no real
prospect of benefit by conventional sur-
gery, radiotherapy or chemotherapy, was
the first to be treated. The plan was
to give Ro 07-0582 (120 mg/kg) in con-
junction with a 6-fraction course of radio-
therapy using an 8-MeV linear accelerator.
A maximum tibsue dose of 3500 rad was
to be given twice weekly, with opposing
portals, over a period of 17 days. This
dose and fractionation is currently em-
ployed with hyperbaric 02 as a standard
treatment for selected cases of recurrent
carcinoma of the rectum and colon
(Dische and Senanayake, 1972; Dische
and Saunders, in preparation).
Immediate drug tolerance was good,
without nausea or vomiting. Good repro-
ducible plasma levels were obtained,
with a mean plateau at 31 h of 136
,ug/ml (s.d. ± 13) (Table I, Fig. 1).
Some reduction of discharge, and some
regression of the tumour, were noted
as early as the third day after the first
treatment, and this improvement con-
tinued. A low-grade pyrexia, considered
due to secondary infection and absorption
of necrotic debris, was observed. The
final treatment was given on Day 17.
Later that day his general condition
deteriorated, he showed some mental
confusion and episodes of sustained mus-
cular spasm of the limbs which were
difficult for him to overcome. No neuro-
logical abnormalities could be demon-
TABLE I.-The Cases Included, the Doses ofRo 07-0582, the Plateau-phase Plasma Levels
and the Plasma Half-lives
Age
Diagnosis (yr)
Ca rectum 67
Ca breast 51
Ca breast 45
Ca breast 56
Ca cervix in lymph 33
nodes
Ca lung 54
Squamous cell ca in 73
lymph nodes
Ca lung 56
Recurrent leiomyo-
sarcoma ofrectum
Metastatic teratoma
of testis
Recurrent ca
rectum
Ca bladder
Ca bronchus
Ca bladder
Ca bronchus
Recurrent ca
caecum
58
26
57
74
63
65
65
53
Total
Ro
07-0582
(g)
51-0
15-0
30-0
24-0
20-5
30-0
17-5
No.
doses
6
6
6
6
6
No.
days
17
18
17
20
18
Dose
(mg/kg)
Indivi-
dual Total
120 720
40 240
60 360
67 402
74 436
Dos
Indivi-
dual
2 -5
2-5
2-5
3ih
or 4 h
3e plasma
12) level
- mean
±s.d.
Total (,ug/ml)
136+13
65+12
15 91+7
15 92+14
14-6 76+18
Half-life
in plasma
mean+s.d.
(h)
12-7+1-4
11-1+1-5
11-8+1-3
12-9+2-7
14-8+2-4
6 19 64 432 2-5 15 82+2 12-2+0-5
5* 15 72 360 2-5 12-5 91+10 11-3+1-5
24-0 6 18 72 432 2-5 15-0 83+ 10 13-6+0-5
32 -5
32-0
24-5
20-0
21 -0
32-0
28-0
21 -0
20
20
15*
4
3
4
4
4
25
26
21
23
17
18
22
18
24
18
27
20
33
24
110
113
85
99
0oot
385
424
382
440
339
340
396
350
1-0
0-8
1-0
0-8
1-2
09
3-75
3-75
3-77
3 -85
3-68t
16-2
16-4
14-4
15
11 -75
15-18
15-4
12 -9
32+ 8
35+2
43+4
130+11 11-5+2-4
156+12 17-0+1 -9
126+14 15-8+0-8
132+11 12-05+0-7
139+13 8-1+0-7
* Further doses not given because of neuropathy.
t Final dose halved.
Case
No.
Cl
C3
C5
C6
C7
CIO
Cll
C12
C8
C9
C13
C16
C17
C18
C19
C21
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FIG. 1.-Plasma concentration-time curves determined polarographically for Patient Cl, who
received 6 oral doses of 120 mg/kg of Ro 07-0582.
strated that day, but during the following
night he suffered repeated grand mal
convulsions and became unconscious. The
convulsions were controlled with diazepam
and steroids. There were then neuro-
logical signs of a gross bilateral disturb-
ance sited in the upper brain stem, or
in both hemispheres. A repeat brain
scan showed a normal result.
Over the next 2 weeks his conscious-
ness gradually lightened, until he was
able to answer simple questions and
some of the neurological signs reverted
to normal. He remained, however, con-
siderably impaired intellectually. Tumour
regression continued and, in the perineal
region, appeared complete. He died 8
weeks after the end of his treatment,
due to a respiratory infection and pul-
monary metastases. A post-mortem ex-
amination showed a 15-cm mass occupying
the pelvis. Much of the tumour was
necrotic, but the upper edge appeared
viable.
There seemed no doubt that the
neurotoxicity was induced by Ro 07-0582,
and a considerable reduction was neces-
sary for further work.
The next patient was given 6 doses
of Ro 07-0582 at one third the previous
level the individual dose being 40 mg/kg.
There were no problems of tolerance,
repeatable plasma levels were obtained,
and no neurological symptoms or signs
developed. For further patients it was
decided that it would be better to base
the dose on surface area rather than on
body weight. Six patients were given
Ro 07-0582 in 6 doses, each based on
2-5 g/m2. For the first patient, this was
equivalent to 60 mg/kg body wt. A
further 3 patients were given the sensit-
izer daily. For them the total dose of
the drug was similar to that for those
given 6 doses. With the limitation of
the 500-mg tablets, it was decided to
standardize the dose to 2 g on Monday
and 1-5 g from Tuesday to Friday. This
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FIG. 2. Plasma concentration-time curves determined polarographically for Patient CIO, who
received 6 oral doses of 2 5 g/m2 (64 mg/kg) of Ro 07-0582.
dosage regime was devised in recognition
that the half-life of 10 to 12 h would
leave residual Ro 07-0582 in the plasma
at 24 h. In each of the 3 cases, 20 treat-
ments were planned over 4 weeks.
Immediate tolerance was good in all
9 cases, and nausea and vomiting were
entirely absent. Satisfactory high plasma
levels were achieved which, in general,
were reproducible throughout the course
of treatment (Table 1, Figs. 2 and 3). In
no case was there any convulsive or
any pre-convulsive episode. However,
8/9 patients subsequently developed a
peripheral neuropathy. Symptoms ofthis
peripheral neuropathy first appeared be-
tween 15 and 29 days after the first dose
of Ro 07-0582 (Tables II and III). In
2 cases, the symptoms presented before
the final dose was due, and in these the
drug was discontinued. At the onset,
symptoms appeared as commonly in the
hands as in the feet, and were variously
reported as pins and needles, numbness,
coldness, dead feeling or loss of feeling.
Later, some patients described an in-
ability to perform fine movements such
as the fastening of buttons, and walking
was interfered with because of loss of
touch and position sense in the feet. Pain
was complained of, and described as
burning, shooting or like tight bands
around wrists or ankles. In some, the
pain was very troublesome and required
strong analgesia to control it. Patients
commonly found that the symptoms were
made worse by hot baths. Some were
considerably disabled by their symptoms
for a period of time.
Symptoms always preceded signs.
There was only a weak correlation between
the grading of symptoms and of signs.
Alteration in the acuity of appreciation
of light touch and pinprick was most
commonly found, often with delay in
their recognition. Usually the findings
were limited to the toes and fingers,
but extension to hands and feet and to
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forearms and lower legs was sometimes
observed. No motor change was elicited
in any case. Electromyographic studies
in 3 cases showed in all the appearance
of a mild peripheral neuropathy. Symp-
toms and signs were graded as follows:
Symrptoms
1. No interference with normal acti-
vities.
2. Some disability, e.g. difficulty in
walking orfastening buttons, paraesthesiae
or pain, keeping the patient awake at
night.
3. Severe disability, e.g. confining the
patient to the house, or pain requiring
strong analgesia.
Signs
1. Confined to fingers and/or toes.
2. Extension to the hands or feet.
3. Extension above wrist or ankle.
In 2 patients, the symptoms and
signs have cleared and the period with
neuropathy was relatively short. It is
noteworthy that these were the 2 youngest
of all the patients (Table II). In the
remaining 6 cases, the neuropathy per-
sists, but is slowly lessening, leaving
disability in only one case.
The peripheral neuropathy seemed
most severe in patients given daily
doses, even though the total dose was
similar to that when 6 doses were given.
For this reason, it was decided to reduce
the number of administrations further,
and to give the same total amount of
Ro 07-0582 in 4 doses combined with the
first 2 and the last 2 treatments in a
6-fraction course of radiotherapy given
over a period of 17-18 days. Vitamins
BJ, B6 and B12 and folic acid levels were
determined in some of the patients with
neuropathy, and were found to be normal
in all cases. The administration of the
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TABLE II.-Incidence of Neurotoxicity and Severity of Peripheral Neuropathy. The
Grading of the Symptoms and Signs is Described in the Text. The Indices are Cal-
culated by Adding Together the Gradingfor Each Week during the Period ofNeuropathy
Peripheral neuropathy
I A
Neurotoxicity
(PN=Peripheral
neuropathy)
Convulsion
None
None
PN
PN
PN
PN
PN
PN
PN
PN
None
PN
PN
PN
None
Onset
(days after
first dose of
Ro 07-0582)
17
0
0
28
17
23
15
22
29
27
20
0
16
25
33
0
Max.
severity
of
symptoms
0
0
1
2
2
2
1
3
2
2
0
1
2
1
0
Max.
severity
of
signs
0
0
1
1
3
2
0
3
0
3
0
3
0
Symptom
index
0
0
28
12
53
21
26
57
12
31
0
28
23
10
0
Sign Duration
index (weeks)
0
0
16
1
59
21
0
52
1
14
0
30
0
15
0
0
0
30*
12
29*
17
28*
30*
13
27*
0
17*
17*
15*
0
* Continuing.
TABLE III.--Weekly Severity ofSymptoms and Signs (Case C1O)
Week
A\
I
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Symptoms 0 0 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1
Signs 0 0 0 3 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Time is measured from the day of the first of 6 doses of Ro 07-0582. The last dose was on Day 19,
and on Day 23 the patient noted pins and needles of toes and then of fingers. The paraesthesia gradually
spread up to the knees but remained at the finger-tips. On Day 27 diminution of appreciation of light
touch and ofpain in the fingers and in his legs up to his knees was demonstrated; temperature and vibration
sense were reduced up to his ankles. By Week 7, his symptoms were stable, with paraesthesiae ofhis fingers
and feet. He had difficulty in walking because his feet " felt so odd ". At this time, the signs were
limited to his fingers and feet. At Week 26, the paraesthesiae of his fingers and feet was still present, but
no longer troubled him, although his signs remained static. For grading of symptoms and signs see text.
B vitamins orally and i.v. did not appear
to modify the symptoms due to the
neuropathy when it had developed. How-
ever, it seemed possible that the prophy-
lactic administration of large amounts
of vitamins of the B group might in-
fluence the production of neuropathy, as
has been shown with isoniazid (W.II.O.,
1963). Each of the 5 patients in this
final group was given B vitamins starting
immediately before the first dose of Ro
07-0582 and continuing through the
course of treatment. A total of 30 mg
thiamine HCl, 12 mg ribofiavine, 120 mg
nicotinamide and 112 mg pyridoxine was
given each day. Tolerance of Ro 07-0582
was once again good, and reproducible
plasma levels were obtained (Table I).
In 3/5 patients a peripheral neuropathy
developed, and in one the final dose
of Ro 07-0582 was not given because
of the appearance of this complication
(Table II).
Three of these patients also developed
evidence of a transient neuropathy during
the evening and night after the ad-
ministration of individual doses of Ro
07-0582. It occurred after the first and
second dose in C18, after all except the
last in C19 and after the third dose in
Case No.
C1
C3
C5
C6
C7
CIO
Cll
C12
C8
C9
C13
C16
C17
C18
C19
C21
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TABLE IV.-Concentration of Ro 07-0582 in Tumour Biopsies Taken on the Day of
Treatment
Case C5
Tumour/plasma
(%)
64
42
99
Case C6
Tumour Plasma
cone. conc. Tumour/plasma
(pg/g) (jug/lM) ( )
115, 118t 121 95, 97 5
99 102* 97
84, 86t 88 95 5, 98
* Determined from the corresponding plasma Ro 07-0582 concentration-time curve.
t Duplicate assays.
C21. No signs developed, and the
symptoms in all had gone by the next
morning. In C21, the final dose of Ro
07-0582 was halved because of a slight
suspicion of a sustained neuropathy, but
this proved false and neurotoxicity has
not developed subsequently.
In this case, C21, 80 mg of frusemide
were given 4 h after administration of
the 2nd, 3rd and 4th doses, so as to
produce a diuresis. This was an attempt
to reduce the half-life of the drug. The
patient did show a comparatively short
half-life of 8 h after the initial dose, but
this was not significantly altered by the
frusemide given with the subsequent
doses.
No haematological or biochemical ab-
normality was found in any case which
could be attributed to Ro 07-0582. No
adverse effects were noted outside the
central nervous system.
In 3 cases, tumour concentrations of
Ro 07-0582 were determined (Tables IV
and V). In C5 and C6, tumour concen-
trations were measured at 2, 4 and 6 h
after administration of Ro 07-0582. In
5/6 samples, levels close to the concentra-
tion in plasma were obtained. The result
in C5 was low at 4 h, but here some fat
was obviously included in the specimen,
and this could well account for the low
reading.
Evidence that hypoxic areas oftumour
were included inthe specimens is presented
in Fig. 4. The centre portion of a drill
biopsy specimen was found to have a
concentration of 79 ,ug/g of Ro 07-0582
which was 99% of that in the plasma.
TABLE V.-Concentration of Ro 07-0582
in Tumour Biopsies after 5 of 6 Treat-
ments in Case C3
Time
after
Dose admin.
No. (h)
1
2
3
5
6
5
5
5
4-6
5-7
Tumour
cone.
(pg/g)
24
53
62
68
62
Plasma
cone.
(mg/ml)
43*
62*
58*
80*
60*
Tumour/plasma
(%)
56
85
107
85
103
* Determined from the corresponding plasma
Ro 07-0582 concentration-time curve.
Histological examination of the remaining
specimen showed that fibrosis had re-
placed tumour in the material adjacent
to the cut ends, and that tumour cells
survived only around blood vessels.
In C3 we attempted to monitor any
change which might occur as a result
of treatment as the course proceeded.
Tumour concentrations determined at
5 h after administration of 5 of the
doses were, in general, similar to plasma
levels, but were lower in the sample
taken after the first dose. After the
fifth treatment, in addition to the routine
sample, some necrotic debris was aspirated
from the centre of the tumour: here
a concentration 37% ofthat in the plasma
was found.
The concentrations of Ro 07-0582
and its principal metabolite, Ro 05-9963,
were determined in all urine samples.
Only some 25% of the dose given could
be accounted for in the first 48 h after
demonstration. Other metabolites have
been identified, but not yet quantified.
Time
(h)
2
4
6
Tumour
conc.
(jsglg)
63
36
79
Plasma
conc.
(jtg/ml)
98
86*
80
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FiG. 4. The drill biopsy at 6 h after treatment in case C4 yielded a core of tumour 36 mm in length.
This was divided into 3 about equal lengths. The 2 outer pieces were examined histologically, and
can be seen above at x 5 magnification. Selected areas are magnified x 100 below. At the
margins, the tumour is densely cellular without evidence ofnecrosis. Towards the centre, tumour
cells appear to be surviving only around blood vessels and much of the material consists offibrous
tissue. The central piece showed a concentration of 79 yg/g of Ro 07-0582 which was equivalent
to 99% of the plasma level at that time. (Preparation by Dr M. H. Bennett.)
DISCUSSION
The nitroimidazoles have been ex-
tensively employed as trichomonacides.
Of these, the 5-nitroimidazole, metro-
nidazole (Flagyl), has had the most use,
and at the dosage required as a tricho-
monacide, has proved to be a very safe
drug. More recently, when used to con-
trol infections caused by other anaerobic
organisms, higher dose levels have been
employed and, in some cases, have been
continued over long periods of time.
Cases of neurotoxicity due to metro-
nidazole have recently been reported
(Ingham, Selkon and Hale, 1975; Coxon
and Pallis, 1976); the type of neuro-
pathy is similar to that which we have
encountered with Ro 07-0582. The mech-
anism of neurotoxicity is at present
unknown. Biochemical studies concerned
withthe drug and its metabolic breakdown
products are under way in cooperation
with Roche Products Ltd.
The peripheral neuropathy was, per-
haps, most troublesome in the group
of 3 patients given daily doses of Ro
07-0582, and least frequent in the 5
patients given 4 doses, although the
total dose in all 3 groups was similar.
A relationship between the number
ofadministrations andneurotoxicity seem-
ed possible; however, as a means of
expressing tissue exposure to Ro 07-0582,
we have calculated the areas under the
curves when plasma concentration is
plotted against time. We were able to
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TABLE VI.-Tissue Exposure Calculated
in Arbitrary Units (see text) in the
Cases Receiving 4 and 6 Doses of Ro
07-0582, Separated into Those with and
without Neuropathy. Tissue Exposure
seems Significantly Related to Neuro-
toxicity (P- 003)
Case No.
Ci
C3
C5
C6
C7
CIO
C12
C16
C17
C18
C19
C21
Exposure index
Neuropathy No neuropathy
1 84
0 77
1 *27
1 *33
1 *04
1*19
1 *24
1 *31
1 *17
1*16
1 *14
0 77
do this only with those cases with either
4 or 6 doses. The results expressed in
arbitrary units were calculated for the
cases and these were then separated
into " no toxicity " and " toxicity "
groups (Table VI). Tissue exposure ap-
peared significantly related to neuro-
toxicity (P = 0.03). It seems likely that
total tissue exposure is the most signifi-
cant factor, and frequency of dose less
important, in the incidence of toxicity.
The administration of the B vitamins did
not appear to prevent neuropathy.
The estimates oftumour concentration
show that the drug readily passes into
the tumour, and that concentrations
approaching those in plasma are achieved.
It is of interest that similar high tumour
concentrations have been found with the
other nitroimidazole which has been
tested in man as a hypoxic cell sensitizer,
metronidazole (Urtasun et al., 1976).
Evidence has been presented to show
that the drug will penetrate into tissue
likely to contain hypoxic cells, and some
will even reach totally necrotic debris.
The patients reported in this study
all presented with advanced malignant
disease. In 13 cases there was an ex-
tensive tumour in the primary site,
while in 3 metastatic disease was treated.
Tumour response has been followed care-
fully in these patients and, when assessed
at 2 months after initiation of treatment,
regression seemed complete in 8 and
partial in another 8. These responses
are, perhaps, better than might be ex-
pected with conventional radiotherapy.
However, no true estimate as to the
effectiveness of the drug to improve
radiotherapy can be obtained from a
series of uncontrolled cases of this sort.
When a safe, satisfactory regime for
administration of Ro 07-0582, in con-
junction with radiotherapy, is established
then, in controlled studies, the value of
this radiosensitizer in radiotherapy can be
assessed.
In all cases, careful observation was
made of immediate reactions in normal
tissues. The areas irradiated were in
the neck, chest, lower abdomen and
pelvis. All immediate reactions in the
pharynx, oesophagus, lung and bowel
were similar to those encountered when
treatment is given without the sensitizer.
As with tumour response, only a careful
comparison of reactions in a randomized
controlled clinical trial can give a final
answer. Animal work and our study of
skin reaction in man suggests that in
oxygenated tissues there is no increase
in radiation response (Dische et al., 1976).
In recent years there has been con-
siderable interest in multiple treatments
each day with radiotherapy, and some
promising results have been reported
(Choi and Suit, 1975; Svodoba, 1975;
Littbrand, personal communication; Dou-
glas, personal communication). The ad-
dition of Ro 07-0582 to such regimes is
particularly practical when treatment is
given on a limited number of days.
In multiple-fraction studies of the
radiotherapy of animal tumours, it has
been shown that the addition of Ro
07-0582 to certain treatments early and/or
late in a course gives a surprisingly
high gain in effect (Van Putten and
Smink, 1976; Sheldon, personal com-
munication).
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Using Ro 07-0582 with a single dose
of radiotherapy, an enhancement of re-
sponse has been observed (Thomlinson et
al., 1976). It is possible that, in palliative
radiotherapy, single treatments using Ro
07-0582 could replace multiple-fraction
techniques, giving similar palliation with
greater ease for the patient and with less
demand on treatment and hospital facili-
ties.
The incidence of neurotoxicitv in our
patients given multiple doses of Ro
07-0582 was high, amounting to 750"
(12/16). The severity was such that we
must limit the amount of drug to be
given in future work. We believe that
a reduction of 2000 in total dose from
15 g/m2 to 12 g/m2 may give a marked
reduction in morbidity. In our next
series of studies we intend to give no
more than a dose of 12 g/m2 or 300 mg/kg
in any one course. Individual doses of
Ro 07-0582 will not exceed 5 g/m2 or
125 mg/kg.
There is a wide range of clinical
application possible within this dose
limitation. We are now exploring the
use of Ro 07-0582 in a number ofdifferent
ways:
(1) In a low daily dosage.
(2) Combined with all 6 fractions in
a course of radiotherapy over 17 to
18 days.
(3) Employing up to 6 doses combined
uith multiple treatments on each day of
administration.
(4) Adding to certain treatments only
in a multifraction course of radiotherapy.
(5) With single doses of radiotherapy
for palliation.
With the dose limitation we must
consider the radiosensitization to be ex-
pected with use of these differing regimes.
New data on tumour concentrations in
animals and man considerablv influence
the situation.
In radiobiological experiments with
mouse tumours where there was a large
improvement in tumour control, drug
dosages calculated on a mg/kg basis
have been higher than those used in our
patients who suffered neurotoxicitv.
However, in the mouse, the clearance
rate of Ro 07-0582 is comparatively
rapid (1-11 h half-life), and this is re-
flected in estimates of tumour concen-
tration, rarely exceeding 400° of that in
plasma. In contrast, in man where drug
clearance is about 8-fold slower, our
data indicate that tumour levels are
similar to those in plasma. The dose
required for sensitization will, on an
mg/kg basis, be appreciablv lower in man
than in mouse.
An additional benefit of the longer
half-life in man will be the loss of repair
of sub-lethal injury in the hypoxic cells.
This did not contribute to the improved
results in the mouse tumour systems so
far reported. for radiotherapy was by
necessity, due to the short half-life,
given within an hour of administration
of Ro 07-0582.
In Fig. 5 we have shown the enhance-
ment ratio for sensitization of hvpoxic
cultivated Chinese hamster cells as a
function of drug concentration (data
from Adams et al., 1976). Also shown
are the results of the irradiation of skin
made temporarily hypoxic in patients
given single doses of Ro 07-0582 (Dische,
et al., 1976). The similarity of the data
supports the view that all mammalian
cells will respond similarly when irradiated
under hypoxia with the administration
of Ro 07-0582.
The shape of the curve relating en-
hancement ratio to drug concentration
is such that considerable enhancement
is present at relativelv low concentrations
and, as this rises, the increase of benefit
becomes proportionately less.
In our patients given daily doses of
Ro 07-0582, the mean plasma concen-
trations lay between 32 and 43 plg/ml.
Such levels correspond to enhancement
ratios between 1 42 and 1-51. We believe
it should be possible to achieve 20 fig/mi
with acceptable morbiditv, and this should
give an enhancement ratio of 1-3. This
calculation, like the data from the mouse
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FIG. 5.-The sensitizing efficiency ofRo 07-0582. Continuous line: Data for sensitization ofhypoxic
Chinese hamster V79 cells cultured and irradiated in vitro (Adams et al., 1976). 0: Data for
sensitization of hypoxic human skin. (Adapted from Dische et al., 1976.)
tumour systems, does not include any
additional benefit which may be gained
in man because of the prolonged exposure
and loss of repair of sub-lethal injury
sustained by hypoxic cells.
When a patient is given 6 doses of Ro
07-0582, it should be possible to reach a
tumour concentration giving an enhance-
ment ratio of 1 65: a value comparable
to the theoretical single-dose gain factor
predicted for neutron radiotherapy.
Work proceeds to develop other chemi-
cal hypoxic cell sensitizers which may
have a more favourable ratio ofsensitizing
effect to morbidity. However, Ro 07-
0582 shows considerable promise as a
drug likely to improve the results of
radiotherapy. The benefits which may
occur with the introduction ofan effective
hypoxic cell sensitizer are great (Adams
et al., 1976) and there is good encourage-
ment to continue the further testing of
Ro 07-0582.
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